Trial Profile
A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary) ; Brimonidine (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 14 May 2021 Status changed from active, no longer recruiting to completed.
- 07 Apr 2021 Planned End Date changed from 28 Feb 2021 to 30 Apr 2021.
- 07 Apr 2021 Status changed from recruiting to active, no longer recruiting.